Brief: Eyepoint Completes Enrollment In Pivotal Phase 3 Lugano Trial Of Duravy For Treatment Of Wet Age-Related Macular Degeneration
27/05/2025 13:17
May 27 (Reuters) - EyePoint Pharmaceuticals Inc EYPT.O: EYEPOINT COMPLETES ENROLLMENT IN PIVOTAL PHASE 3 LUGANO TRIAL OF DURAVYU™ FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION EYEPOINT PHARMACEUTICALS INC - LUCIA PHASE 3 TRIAL EXPECTED TO COMPLETE ENROLLMENT IN 3Q 2025 Source text: ID:nGNX2TQb4S Further company coverage: EYPT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on EyePoint
See all newsUS RESEARCH ROUNDUP-Axon Enterprise, Williams-Sonoma, Xcel Energy
US STOCKS ON THE MOVE-CoreWeave, Moderna, Datadog
U.S. STOCKS ON THE MOVE-Amazon, CoreWeave, Moderna
U.S. STOCKS ON THE MOVE-Centrus Energy, Disc Medicine, Crypto
EyePoint to halve workforce after experimental drug fails second late-stage trial (updated)